Mustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020 Oct 01, 2020
Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy) Oct 01, 2020
Mustang Bio Announces Orphan Drug Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients Sep 22, 2020
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma Sep 17, 2020
Checkpoint Therapeutics to Participate in Three September 2020 Virtual Investor Conferences Sep 10, 2020
